KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other financing activities (2017 - 2025)

Historic Other financing activities for Aquestive Therapeutics (AQST) over the last 7 years, with Q3 2025 value amounting to $7000.0.

  • Aquestive Therapeutics' Other financing activities fell 1250.0% to $7000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3000.0, marking a year-over-year increase of 10003.8%. This contributed to the annual value of $4.6 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Other financing activities is $7000.0, which was down 1250.0% from $8000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Other financing activities high stood at $9.1 million for Q1 2023, and its period low was -$7.9 million during Q4 2023.
  • For the 3-year period, Aquestive Therapeutics' Other financing activities averaged around $424000.0, with its median value being $6000.0 (2025).
  • Data for Aquestive Therapeutics' Other financing activities shows a peak YoY increase of 9977.23% (in 2024) and a maximum YoY decrease of 9994.5% (in 2024) over the last 5 years.
  • Aquestive Therapeutics' Other financing activities (Quarter) stood at -$7.9 million in 2023, then soared by 99.77% to -$18000.0 in 2024, then surged by 138.89% to $7000.0 in 2025.
  • Its Other financing activities was $7000.0 in Q3 2025, compared to $8000.0 in Q2 2025 and $6000.0 in Q1 2025.